Compare DHC & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHC | NVAX |
|---|---|---|
| Founded | 1998 | 1987 |
| Country | United States | United States |
| Employees | 585 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | N/A | 1996 |
| Metric | DHC | NVAX |
|---|---|---|
| Price | $6.72 | $8.46 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 9 |
| Target Price | $7.25 | ★ $11.33 |
| AVG Volume (30 Days) | 2.0M | ★ 4.4M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.58% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $3.13 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | ★ N/A | $3.47 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $2.00 | $5.01 |
| 52 Week High | $7.66 | $11.85 |
| Indicator | DHC | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 46.64 | 38.12 |
| Support Level | $3.85 | $8.01 |
| Resistance Level | $6.85 | $9.05 |
| Average True Range (ATR) | 0.30 | 0.54 |
| MACD | -0.10 | -0.23 |
| Stochastic Oscillator | 20.76 | 1.81 |
Diversified Healthcare Trust is a real estate investment trust that focuses on healthcare-related properties, including life science estates, medical offices, and senior living communities. It acquires and owns properties and is engaged in the development and implementation of medical services and technologies. The company has two reportable segments: SHOP (Senior Housing Operating Portfolio) and Medical Office and Life Science Portfolio. The SHOP segment includes managed senior living communities providing residential living and care services. The Medical Office and Life Science Portfolio segment consists of properties leased to medical providers and biotechnology laboratories. It generates the majority of its revenue from the SHOP segment.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.